Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide Long-Term Safety in Type 1 Diabetes (137-150E)
NCT00107107Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2002
- Primary completion
- Jun 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pramlintide in type 1 diabetes mellitus (T1D), sponsored by AstraZeneca. Primary endpoints: Long-term safety profile at 6 months and Change in body weight at 6 months. Started Nov 2002; status: completed.
02
Drugs
pramlintide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00107107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107107.